Ruihai Zhou, MD, RPVI, FACC

interventional cardiologist for peripheral dz as well. Also got trained in pharmacology, clinical pharmacology, cell and molecular biology, & translational med

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@DrToddLee @NEJM @PaulSaxMD That is just an example. Focused physical exam is ok. I meant tests cannot replace “seeing” a patient.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@JACCJournals It is biased to establish “causality” using Mendelian (so called ) Randomization Study due to its intrinsic weakness to infer unknown with limited knowns. The way to establish causality is to check the effects after Lp(a) is specifically inhibited. Let’s wait for the trials

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@IhabFathiSulima Following. Please post your answer in time for teaching purposes 😀

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@JAMACardio @JAMACardio The tweet context is not consistent w/ findings

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@JAMACardio The tweet context is not consistent w/ findings

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@ESC_Journals ? Inconsistent

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@NEJMClinician @NEJM Even blur the abstract? Must be top secret 😀

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@RitikaTuliMD This order is not always true

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@NEJM NEJM publications often appear later on PubMed and are not synchronized with PubMed unlike many other journals, although many institutions provide library access to NEJM through PubMed.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@NEJM @MassGeneralNews Nice case!

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

Thank you for publishing our article!@JACCJournals @UNCCardiology @UNCDeptMedicine @GilbertTangMD #JACCCaseReports Regadenoson is considered to be safe for cardiac stress test. However as FDA warns, serious side effects including STEM may happen, although rare. Awareness !

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

Raising Awareness of ST-Segment Elevation Myocardial Infarction Triggered by Intravenous Regadenoson for Cardiac Stress Testing | JACC: Case Reports https://t.co/4sAtvpeqAM

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

Raising Awareness of ST-Segment Elevation Myocardial Infarction Triggered by Intravenous Regadenoson for Cardiac Stress Testing | JACC: Case Reports https://t.co/Q5hiX1hrcu

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@CircAHA Clinical trials, not with surrogate marker but hard clinical outcome endpoints, on Lp(a) “inhibitors” are eagerly awaited.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@CircAHA It can be far away from association or relation to be come causality. Mendelian randomization has intrinsic limitation itself.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@CircAHA It is reasonable to say that it is a biased overstatement to say Lp(a) is causal for those CV diseases based on Mendelian randomization trials or epidemiological data until data showing inhibiting Lp(a) in different ways reduces CV events, with hard endpoints, are available.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@CircAHA It is reasonable to say that it is a biased overstatement to say Lp(a) is causal for those CV diseases based on Mendelian randomization trials or epidemiological data until data showing inhibiting Lp(a) in different ways reduces CV events, with hard endpoints, are available.

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@purviparwani So tragic. Sending love and prayers to all the families there!

[Ruihai Zhou, MD, RPVI, FACC @RZhou15]

@JWatch @SheaHogan7 Until clinical outcome (ideally “hard”endpoints, instead of composite w soft ones or surrogate endpoints) data on Lp(a) specific inhibitor are available, it is safe to say Lp(a) is no more than a parameter to gauge the risk of ASCVD.